Apr 27, 2021 / 02:30PM GMT
Operator
Good morning, and welcome to the Lumos Pharma KOL webinar on LUM-201 for the treatment of pediatric growth hormone deficiency. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Lumos Pharma website following the event.
I would now like to turn the call over to your host, Rick Hawkins, Chief Executive Officer of Lumos Pharma. Please go ahead, Rick.
Richard J. Hawkins - Lumos Pharma, Inc. - Founder, Chairman, CEO & President
Good morning, and thank you for joining us for our KOL event on pediatric growth hormone deficiency in LUM-201, Lumos Pharma's therapeutic candidate targeting PGHD. I'm Rick Hawkins, CEO, Chairman, President of Lumos Pharma. I'll be joined by 2 noted thought leaders in the field of pediatric endocrinology for our discussion.
Before we proceed with our program, I'd like to remind everyone that certain statements made during this event are considered forward-looking statements under U.S. federal securities laws. Actual results may differ materially from the
Lumos Pharma Inc Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study-Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
